Patents Issued in May 2, 2019
  • Publication number: 20190125818
    Abstract: This disclosure relates to extracts from chestnut plants and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the leaves of a Castanea plant. In certain embodiments, the disclosure relates to methods of treating or preventing bacterial infections, acne, and other related uses.
    Type: Application
    Filed: December 19, 2018
    Publication date: May 2, 2019
    Inventors: Cassandra L. Quave, James Lyles, Alexander R. Horswill
  • Publication number: 20190125819
    Abstract: A pharmaceutical composition and a health functional food including an oat extract as an effective ingredient for prevention or treatment of neurodegenerative disease. More specifically, the present invention provides a pharmaceutical composition and a health functional food including an oat extract such as avenanthramide C or a derivative thereof, for example, avenanthramide methyl ester as an effective ingredient for prevention or treatment of Alzheimer's disease.
    Type: Application
    Filed: July 4, 2016
    Publication date: May 2, 2019
    Inventors: Ji Hoon JO, Hyung Seok KIM, Yu Young LEE
  • Publication number: 20190125820
    Abstract: The present disclosure relates to the field of health care products. The present disclosure provides a powder which is prepared from xylooligosaccharide, isomaltooligosaccharide, mannitol, inulin, RADIX CODONOPSIS, FRUIT BODY HERICIUM ERINACEUS extract, RHIZOMA DIOSCOREA OPPOSITA, SCLEROTIUM PORIA, SEMEN DOLICHOS, PERICARPIUM CITRUS, FRUCTUS AMOMUM and RHIZOMA MACROCEPHALA. All raw materials are from natural Chinese herbal medicine. No additives are added. The method for preparing the powder in the present disclosure is simple and suitable for large-scale production. Also, it is easy to be carried. Experiment data shows that the powder described in the present disclosure has the function of relieving the gastric mucosal injury by reducing the acute gastric mucosal injury induced by ethanol effectively and has the function of regulating gastric mucosa.
    Type: Application
    Filed: April 18, 2018
    Publication date: May 2, 2019
    Applicant: INFINITUS (CHINA) COMPANY LTD.
    Inventors: Lei WANG, Ruiqi HE, Hongwei ZHAO, Qingtao TANG
  • Publication number: 20190125821
    Abstract: The present invention relates generally to compositions and methods of use that include compounds that treat and prevent rheumatoid arthritis, inflammation, and diseases caused by or having inflammation as a symptom.
    Type: Application
    Filed: March 8, 2017
    Publication date: May 2, 2019
    Inventors: Joshua M COSTIN, John M. WILLIAMS, Dan LI
  • Publication number: 20190125822
    Abstract: An object of the present invention is to provide a composition for preventing or improving fat deposition on the liver in spite of the alcohol intake history of a level that a liver disease is not caused. The inventors found that glutathione has an effect of preventing or improving fat deposition on the liver, which is not caused by alcohol, and completed the present invention. Among nonalcoholic fat diseases, the present invention is particularly effective in an early stage of the treatment or in a case where treatment for another disease is not performed.
    Type: Application
    Filed: December 26, 2018
    Publication date: May 2, 2019
    Applicants: KOHJIN LIFE SCIENCES CO., LTD., PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, SAGA UNIVERSITY
    Inventors: Takaomi KESSOKU, Atsushi NAKAJIMA, Yoshio SUMIDA, Yuichiro EGUCHI, Susumu SAITO, Yusuke SAUCHI
  • Publication number: 20190125823
    Abstract: A method of treatment of pain in a person with a D peptide chemokine receptor antagonist (CRA), and a pharmaceutically acceptable carrier is disclosed. Because chemokines desensitize opiate receptors and enhance the perception of pain said D-peptide CRA, given with a suboptimal dose of an opioid, such as morphine, will restore opioid analgesic efficacy by blocking the cognate chemokine ligand from binding to its receptor and desensitizing the opioid receptor. This strategy of combining a suboptimal dose of morphine with a CRA enhances the potency of morphine, permitting use of lower doses of morphine to obtain equivalent and near maximal analgesia. Lower morphine (opioid) doses have less risk of adverse effects, and potentially also of development of tolerance and dependence.
    Type: Application
    Filed: October 31, 2018
    Publication date: May 2, 2019
    Applicant: Creative Bio-Peptides Inc.
    Inventor: Michael R. Ruff
  • Publication number: 20190125824
    Abstract: Methods of reducing chemical degradant formation, such as those resulting from dimer formation in disulfide bridge-closed ring-bearing polypeptides, such as oxytocin, in a solid-state: to heat stable pharmaceutical compositions having improved physio- or chemical stability, to inhalers and dosage forms of such compositions, to methods of production of and treatment of diseases and or conditions, such as post partum hemhorrage, with such compositions.
    Type: Application
    Filed: October 29, 2015
    Publication date: May 2, 2019
    Inventor: James John MITCHELL
  • Publication number: 20190125825
    Abstract: Methods for treating a bacterial infection and for suppressing antibiotic resistance in a patient are described herein. Certain such methods generally involve administering an antibiotic and an adjuvant compound to a patient with a bacterial infection caused by Staphylococcus aureus, wherein the adjuvant compound comprises a fused tricyclic ring system with at least one halogen substituent. Compositions and kits containing such components are also described.
    Type: Application
    Filed: October 12, 2018
    Publication date: May 2, 2019
    Inventors: Meghan Scobee Blackledge, Patrick Andrew Vigueira, Heather B. Miller
  • Publication number: 20190125826
    Abstract: The present invention relates to methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency. The inventors show, for the first time, that the structural protein DSG1 directly acts as a novel and unexpected inhibitor of epithelial inflammation via the inhibition of NF-?B signaling pathway. In particular, the present invention relates to a method of treating an inflammatory skin disease associated with desmoglein-1 deficiency in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent capable of restoring the expression of desmogelin-1. Particularly, the inventors carried out the whole exome sequencing, histopathological, electron microscopy, immunofluorescence and immunological analyses in two unrelated patients presenting with SAMEC syndrome.
    Type: Application
    Filed: April 21, 2017
    Publication date: May 2, 2019
    Inventors: Christine BODEMER, Asma SMAHI, Elodie BAL, Laura POLIVKA, Smail HADJ-RABIA
  • Publication number: 20190125827
    Abstract: Methods for modulating lysosome-mediated microautophagy of a lipid or protein substrate in a cell are provided herein. In certain embodiments, said methods may comprise increasing lysosome-mediated microautophagy by treating the cell with a microautophagy-enhancing agent which increases lysosomal association-dissociation events between lysosomes and the cellular lipid or protein substrate and/or increases lysosomal degradation capacity; or decreasing lysosome-mediated microautophagy by treating the cell with a microautophagy-reducing agent which reduces lysosomal association-dissociation events between lysosomes and the cellular lipid or protein substrate and/or decreases lysosomal degradation capacity; thereby modulating lysosome-mediated microautophagy of the lipid or protein substrate.
    Type: Application
    Filed: July 8, 2016
    Publication date: May 2, 2019
    Applicant: University of Ottawa
    Inventors: Mohsen Amir Alipour, Zemin Yao
  • Publication number: 20190125828
    Abstract: The present disclosure provides a single dose form composition to optimize the relationship between the ‘Folate-Cobalamin’ and ‘Choline-Betaine’ pathways. Single dose form compositions disclosed herein ensure an adequate intake of the rate limiting compounds that have been demonstrated to reduce the efficiency of this vital metabolic axis, and methods of use thereof.
    Type: Application
    Filed: March 20, 2017
    Publication date: May 2, 2019
    Inventor: Jonathan Bortz
  • Publication number: 20190125829
    Abstract: The present invention provides methods for reducing a subject's hepatic and plasma triglyceride levels comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutical carrier and a compound that decreases KCTD17 expression in liver cells in an amount effective to reduce the subject's hepatic and plasma triglyceride levels.
    Type: Application
    Filed: April 28, 2017
    Publication date: May 2, 2019
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Utpal Pajvani, Kyeongjin Kim
  • Publication number: 20190125830
    Abstract: Disclosed herein is a method of promoting sustained survival, sustained regeneration, in a lesioned mature neuron, sustained compensatory outgrowth in a neuron, or combinations thereof. The method comprises contacting the lesioned mature neuron with an effective amount of an inhibitor of PTEN and an effective amount of an inhibitor of SOCS3 to thereby promote survival and/or regeneration and/or compensatory outgrowth of the neuron. Therapeutic methods of treatment of a subject with a neuronal lesion by administration of a therapeutically effective amount of an inhibitor of PTEN and a therapeutically effective amount of an inhibitor of SOCS3, are also disclosed, as are pharmaceutical compositions and devices for use in the methods.
    Type: Application
    Filed: December 19, 2018
    Publication date: May 2, 2019
    Applicant: Children's Medical Center Corporation
    Inventors: Zhigang He, Duo Jin, Fang Sun
  • Publication number: 20190125831
    Abstract: As microbial drug-resistance increases, there is a critical need for new classes of compounds to combat infectious diseases. The Ixodes scapularis tick antifreeze glycoprotein, IAFGP, functions as an anti-infective agent against diverse bacteria including methicillin-resistant Staphylococcus aureus. Recombinant IAFGP and a peptide, P1, described herein and derived from this protein, bind to microbes and alter biofilm formation. Transgenic iafgp-expressing flies and mice challenged with bacteria, as well as wild-type animals administered IAFGP or P1, were resistant to infection, septic shock, or biofilm development on implanted biomaterials. Antifreeze protein controls bacterial infection and present new therapeutic strategies to counter pathogens.
    Type: Application
    Filed: September 6, 2018
    Publication date: May 2, 2019
    Applicants: Yale University, Howard Hughes Medical Institute
    Inventors: Erol Fikrig, Martin Heisig, Nabil Abraham, Girish Neelakanta
  • Publication number: 20190125832
    Abstract: The present invention relates to a pharmaceutical composition for ameliorating the symptoms and disease of the respiratory infection caused by human Metapneumovirus (hMPV), which comprises at least one agent that neutralizes the function of TSLP and/or TSLPR and/or OX40L and/or CD177 molecules, and a pharmaceutically acceptable excipient, wherein the agent is selected from monoclonal antibodies, biological or synthetic molecules. More specifically, the neutralizing agents are humanized anti-TSLP, anti-TSLPR, anti-OX40L and anti-CD177 monoclonal antibodies. The use of said composition for preparing a medicament for treating or ameliorating the symptoms and disease of patients infected with human Metapneumovirus (hMPV) is also described.
    Type: Application
    Filed: April 15, 2016
    Publication date: May 2, 2019
    Inventors: Alexis Mikes KALERGIS PARRA, Margarita Kam-Lem LAY REMOLCOI, Susan Marcela BUENO RAMIREZ
  • Publication number: 20190125833
    Abstract: Methods of treating muscle wasting and other disorders with NOPE extracellular domain (ECD) polypeptides and NOPE ECD fusion molecules are provided.
    Type: Application
    Filed: April 24, 2017
    Publication date: May 2, 2019
    Applicants: Five Prime Therapeutics, Inc., Glaxosmithkline Intellectual Property Development Limited
    Inventors: Aaron Curtis Hinken, Amy W. Hsu, Janine Powers, Warren James Rocque, Alan James Russell
  • Publication number: 20190125834
    Abstract: The present invention provides a recombinant fusion protein containing an anti-PD-L1 antibody, with at least one paratope of the anti-PD-L1 antibody linked via a linker to an extracellular Ig-like domain of a signal-regulator protein (SIRP) at N-terminus of a heavy chain or a light chain, wherein the recombinant fusion protein can bind to CD47, PD-L1 and FcR simultaneously. The present invention also provides a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of CD47 and/or PD-L1 using the recombinant protein.
    Type: Application
    Filed: October 24, 2018
    Publication date: May 2, 2019
    Inventors: Wenzhi TIAN, Song LI
  • Publication number: 20190125835
    Abstract: A method of preventing or treating cutaneous pigmentation disease in a subject in need thereof, includes: providing a pharmaceutical composition comprising SDF1, an inducer or activator of SDF1, as an active ingredient; and administering the pharmaceutical composition to the subject, wherein the cutaneous pigmentation is prevented or treated, and the cutaneous pigmentation disease is selected from the group consisting of melasma, freckles, lentigo, nevus, pigmentation by drugs, pigmentation after inflammation and hyperpigmentation incurred from dermatitis.
    Type: Application
    Filed: October 30, 2018
    Publication date: May 2, 2019
    Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Hee Young KANG, Tae Jun PARK, Jung Eun YOON, Mi Sun KIM
  • Publication number: 20190125836
    Abstract: Disclosed are methods and compositions useful in preventing or treating a disease related to muscle wasting by using acidic fibroblast growth factor (aFGF).
    Type: Application
    Filed: October 30, 2018
    Publication date: May 2, 2019
    Applicant: Eusol Biotech Co., Ltd.
    Inventors: Hung-Kai CHEN, Jing-Yi HUANG, Huey-Wen HSIAO, Che-Ming YEH
  • Publication number: 20190125837
    Abstract: The present invention is in the field of medicine and provides means and methods for the treatment, prevention or amelioration of osteoarthritis. More in particular, it provides a peptide for use in the treatment, amelioration or prevention of osteoarthritis, wherein the peptide is between 12 and 28 amino acids in length and comprises an amino acid sequence according to SEQ ID NO: 16 or a variant thereof according to formula 2, wherein the amino acid sequence of said peptide is comprised in SEQ ID NO: 34 or a variant thereof according to formula 1.
    Type: Application
    Filed: March 31, 2017
    Publication date: May 2, 2019
    Inventors: Tim Johannes Maria Welting, Marjolein Maria Johanna Caron
  • Publication number: 20190125838
    Abstract: The present invention is in the field of medicine and provides means and methods for the treatment, prevention or amelioration of osteoarthritis. More in particular, it provides a peptide for use in the treatment, amelioration or prevention of osteoarthritis, wherein the peptide consists of an amino acid sequence according to SEQ ID NO: 18 or an analogue thereof, wherein the analogue is a peptide consisting of an amino acid sequence according to formula 1 (SEQ ID NO: 29), or a fragment thereof wherein the fragment consists of at least 10 consecutive amino acids of SEQ ID NO: 18 or an amino acid sequence according to formula 1.
    Type: Application
    Filed: March 31, 2017
    Publication date: May 2, 2019
    Inventors: Tim Johannes Maria Welting, Marjolein Maria Johanna Caron
  • Publication number: 20190125839
    Abstract: The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides.
    Type: Application
    Filed: November 15, 2018
    Publication date: May 2, 2019
    Inventors: Joshua FREDERICK, Susannah HEWITT, Ailin BAI, Stephen HOGE, Vladimir PRESNYAK, Iain MCFADYEN, Kerry BENENATO, Ellalahewage Sathyajith KUMARASINGHE
  • Publication number: 20190125840
    Abstract: The present invention relates to a combination comprising at least fusion protein comprising a binding protein specifically recognizing a cancer-related antigen and an inflammatory cytokine, and a chimeric antigen receptor (CAR)-T cell recognizing a cancer-related antigen.
    Type: Application
    Filed: April 12, 2017
    Publication date: May 2, 2019
    Inventors: Wolfgang Berdel, Claudia Rossig, Christoph Schliemann, Bianca Altvater, Sareetha Kailayangiri
  • Publication number: 20190125841
    Abstract: The present invention provides, among oilier things, compositions and methods for CNS delivery of lysosomal enzymes (e.g., recombinant human arylsulfatase A (rhASA)) for effective treatment of lysosomal storage diseases (e.g. Metachromatic Leukodystrophy Disease), In some embodiments, the present invention includes a stable formulation for intrathecal administration comprising an ASA protein and a poloxamer, wherein less than 3% of the ASA protein exists in aggregated form.
    Type: Application
    Filed: June 5, 2018
    Publication date: May 2, 2019
    Inventors: Nazila Salamat-Miller, Katherine Taylor, Paul Campolieto, Zahra Shahrokh, Jing Pan, Lawrence Charnas, Teresa Leah Wright, Pericles Calias, Keethkumar Jain, Sujit Basu
  • Publication number: 20190125842
    Abstract: The present invention comprises methods and compositions for the treatment or alleviation of NAFLD (non-alcoholic fatty liver disease) and those conditions associated with NAFLD, including fatty liver disease, nonalcoholic steatohepatitis (NASH) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating The Metabolic Syndrome.
    Type: Application
    Filed: September 26, 2018
    Publication date: May 2, 2019
    Inventor: Gregory A. Grabowski
  • Publication number: 20190125843
    Abstract: A method and pharmceutical compositon for the treatment of thrombotic thrombocytopenic purpura. The method and pharmceutical compositon uses a therapuetically effective amount of an antiplatelet thrombolysin comprising two polypeptide chains, an alpha chain and a beta chain. The antiplatelet thrombolysin of the invention can limit platelet adhesion and aggregation, restore platelets, red blood cell and hemoglobin levels, at the same time, reduce the level of lactate dehydrogenase, and effectively inhibits thrombocytopenia and schistocyte hemolytic anemia, so as to achieve the purpose of the treatment of TTP, which has a good prospect of clinical use.
    Type: Application
    Filed: April 22, 2016
    Publication date: May 2, 2019
    Applicant: Zhaoke Pharmaceutical (HEFEI) Company Limited
    Inventors: Xiaoyi Li, Xiangrong Dai
  • Publication number: 20190125844
    Abstract: Disclosed herein are compositions and methods for use in reducing lung function inhibition.
    Type: Application
    Filed: November 1, 2018
    Publication date: May 2, 2019
    Inventors: Fauad Hasan, Wajdie Ahmad, Sawsan Abushakra
  • Publication number: 20190125845
    Abstract: Provided herein are improved compositions and methods for enzyme replacement therapy using modified human cystathionine beta synthase (CBS) in the treatment of homocystinuria and related diseases and disorders.
    Type: Application
    Filed: January 9, 2019
    Publication date: May 2, 2019
    Inventors: Jan P. Kraus, Tomas Majtan, Erez Bublil
  • Publication number: 20190125846
    Abstract: The invention relates to a method comprising the step of incubating chitosan in an aqueous solution of an organic carboxylic acid or a salt thereof, a modified chitosan obtainable by the method of the present invention, a hydro colloid, a compound of formula [X]n, a composition comprising the modified chitosan, the hydro colloid or compound according to the present invention, the modified chitosan, the hydro colloid, the compound or composition according to the present invention for use in human and/or veterinary medicine and the modified chitosan, the hydro colloid, the compound or composition according to the present invention for use in a method of treating and/or preventing mastitis, preferably latent mastitis and/or acute mastitis, endometritis, preferably chronic, acute and/or purulent-catarrhal endometritis, hoof- and claw diseases, lameness, lesions in the interdigital space, digital dermatitis, interdigital dermatitis, interdigital phlegmon, trichophytosis, microsporosis, mycosis of skin, allergies,
    Type: Application
    Filed: March 15, 2017
    Publication date: May 2, 2019
    Inventors: Igor POLYAKOV, Liudmila IVANOVA
  • Publication number: 20190125847
    Abstract: The present invention pertains to a dendritic cell-based vaccine against rh-?-Syn, ?-synuclein specific peptide antibodies and related vaccines, and methods of treating, inhibiting, and/or vaccinating against Parkinson's Disease (PD), or symptoms thereof.
    Type: Application
    Filed: December 14, 2018
    Publication date: May 2, 2019
    Applicant: University of South Florida
    Inventors: CHUANHAI CAO, XIAOYANG LIN
  • Publication number: 20190125848
    Abstract: The present invention provides compositions and methods for treating cancer.
    Type: Application
    Filed: March 30, 2016
    Publication date: May 2, 2019
    Inventors: Donald Kufe, David Avigan
  • Publication number: 20190125849
    Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material.
    Type: Application
    Filed: October 25, 2018
    Publication date: May 2, 2019
    Applicants: President and Fellows of Harvard College, Regents of the University of Michigan
    Inventors: David J. Mooney, Omar Abdel-Rahman Ali, Eduardo Alexandre Barros E Silva, Hyun Joon Kong, Elliot Earl Hill, JR., Tanyarut Boontheekul
  • Publication number: 20190125850
    Abstract: Disclosed is a composition comprising an immunogenic composition for use in treatment of squamous cell carcinoma in combination with myeloid-derived suppressor cell-inhibiting agents as well as a corresponding method of treatment.
    Type: Application
    Filed: June 6, 2017
    Publication date: May 2, 2019
    Inventors: Irena ADKINS, Nada HRADILOVÁ, Ondrej PALATA, Radek SPISEK
  • Publication number: 20190125851
    Abstract: A method generally includes co-administering to a subject a composition that includes an antigen and a cytokine signaling immunomodulator. The method can be for treating a subject for abuse of a drug, treating a subject for toxicity from drug abuse, treating a subject for infection by a pathogen, treating a subject for a non-communicable disease, or for increasing antibody production against the antigen. The antigen can be component of a vaccine. The cytokine-signaling immunomodulator is effective to improve the subject's immune response to the antigen compared to the subject's immune response to the antigen without the cytokine-signaling immunomodulator.
    Type: Application
    Filed: May 10, 2017
    Publication date: May 2, 2019
    Inventor: Marco Pravetoni
  • Publication number: 20190125852
    Abstract: Methods and compositions for constructing and producing recombinant adenovirus-based vector vaccines are provided. In particular aspects, there are be provided compositions and methods involving adenovirus vectors comprising genes for target antigens, such as pro state-specific antigen (PSA), pro state-specific membrane antigen (PSMA), MUC1, CEA, and/or Brachyury, and costimulatory molecules for use in treatment methods that generate highly reactive anti-tumor immune responses and that allows for multiple vaccinations in individuals with preexisting immunity to adenovirus.
    Type: Application
    Filed: June 2, 2017
    Publication date: May 2, 2019
    Inventors: Frank R. JONES, Joseph BALINT, Yvette LATCHMAN, Adrian RICE, Elizabeth GABITZSCH
  • Publication number: 20190125853
    Abstract: The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.
    Type: Application
    Filed: May 31, 2018
    Publication date: May 2, 2019
    Inventors: Charles RICHARDSON, Thomas S. VEDICK, Thomas R. FOUBERT, William T. TINO
  • Publication number: 20190125854
    Abstract: Novel nucleic acid molecules encoding a pre-fusion RSV F protein or immunologically active part thereof are described, and the pre-fusion RSV F protein contains the amino acid sequence of SEQ ID NO: 1 or 2. Use of the nucleic acid molecules, or vectors containing the nucleic acid molecules, as a vaccine against respiratory syncytial virus (RSV) is also described.
    Type: Application
    Filed: April 4, 2017
    Publication date: May 2, 2019
    Inventors: Johannes Petrus Maria LANGEDIJK, Janneke M. VERHAGEN
  • Publication number: 20190125855
    Abstract: The present invention relates to a method of generating a live attenuated vaccine. The present invention also relates to a live attenuated vaccine produced according to the method of the invention.
    Type: Application
    Filed: April 13, 2017
    Publication date: May 2, 2019
    Applicant: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Eng Eong OOI, Kenneth GOH, Swee Sen KWEK, Choon Kit TANG
  • Publication number: 20190125856
    Abstract: The present invention relates to an immunogenic polypeptide comprising a multitude of human papillomavirus (HPV) L2 N-terminal peptides corresponding to amino acids 20 to 50 of the L2 polypeptide of HPV16, wherein said HPV L2 N-terminal peptides are L2 N-terminal peptides from at least two different HPV genotypes. The present invention also relates to said immunogenic polypeptide for use in medicine and for use in vaccination against HPV infection. Moreover, the present invention relates to a polynucleotide encoding the immunogenic polypeptide and to a host cell comprising the same. Moreover, the present invention relates to kits, methods, and uses related to the immunogenic polypeptide of the invention.
    Type: Application
    Filed: June 7, 2017
    Publication date: May 2, 2019
    Inventors: Angelo Bolchi, Martin Müller, Simone Ottonello, Somayeh Pouyanfard, Gloria Spagnoli
  • Publication number: 20190125857
    Abstract: The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Norovirus or a disorder related to such an infection. In particular, the present invention concerns a Norovirus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.
    Type: Application
    Filed: May 4, 2017
    Publication date: May 2, 2019
    Inventors: Susanne RAUCH, Kim Ellen SCHMIDT, Benjamin PETSCH
  • Publication number: 20190125858
    Abstract: Compositions and methods are provided for a live, attenuated influenza vaccine suitable for nasal administration. The vaccine utilizes a cold adapted influenza virus that lacks virulence factor, and includes mutations that provide replicative ability sufficient for vaccine manufacture. Vaccines so produced provide significant cross protection for non-vaccinating strains. The vaccine is safe for children under the age of 2 and adults over 49 years of age. In addition, the cold adapted, virulence factor deleted influenza virus can be adapted to provide immunity to non-influenza pathogens.
    Type: Application
    Filed: April 18, 2017
    Publication date: May 2, 2019
    Inventors: Honglin CHEN, Min ZHENG, Pui WANG, Johnson Yiu-Nam LAU, Kwok Yung YUEN
  • Publication number: 20190125859
    Abstract: Provided herein are immunization regimens for inducing an immune response (e.g., and antibody response) against influenza virus. In specific aspects, the immunization regimens involve the administration of a chimeric hemagglutinin (HA), a headless HA or another influenza virus stem domain based construct (e.g., the HA stem domain or a fragment thereof) to a subject. In certain aspects, the immunization regimens also involve the administration of an influenza virus neuraminidase immunogen. Also provided herein are immunogenic/vaccine compositions for use in methods of immunizing or immunization regimens for human subjects against influenza virus.
    Type: Application
    Filed: June 1, 2017
    Publication date: May 2, 2019
    Applicants: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Peter PALESE, Adolfo GARCIA-SASTRE, Florian KRAMMER, Raffael NACHBAGAUER, Bruce INNIS, Corey Patrick MALLETT
  • Publication number: 20190125860
    Abstract: The present invention provides compositions and methods related to equine live-attenuated influenza vaccines.
    Type: Application
    Filed: June 2, 2017
    Publication date: May 2, 2019
    Inventor: Luis Martinez-Sobrido
  • Publication number: 20190125861
    Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.
    Type: Application
    Filed: January 8, 2019
    Publication date: May 2, 2019
    Inventors: Ye Che, Philip Ralph Dormitzer, Alexey Vyacheslavovich Gribenko, Luke David Handke, Avvari Krishna Prasad, Xiayang Qiu, Mark Edward Ruppen, Xi Song, Kena Anne Swanson, Srinivas Kodali, Xin Xu, KariAnn Sweeney Efferen, Ping Cai, Kristin Rachael Tompkins, Lorna del Pilar Nunez
  • Publication number: 20190125862
    Abstract: The present invention relates to the production of structural proteins and virus-like particles (VLPs) of flaviviruses and hepatitis C. Production is through use of a single expression cassette comprising a viral structural gene, a furin encoding gene and a bicistronic expression element such as an internal ribosome entry site (IRES) between the viral and furin genes. Both the viral gene and furin gene can include a partial capsid encoding sequence acting as a signal peptide to co-locate the viral protein and furin and to act as a membrane anchor for the viral protein and furin. A separate expression cassette comprising a non-structural viral gene can be combined with the initial cassette. The structural proteins and VLPs can be used in vaccines and in the treatment of viral infections.
    Type: Application
    Filed: April 19, 2017
    Publication date: May 2, 2019
    Inventors: Mary Jane CARDOSA, Katharine BOSSART
  • Publication number: 20190125863
    Abstract: The invention provides a nanoemulsion adjuvant and a preparation method thereof, which are composed of the following components: a continuous aqueous phase containing H2O molecules, an oil phase material containing fats and oils, and an emulsion system for stabilizing the interface between the continuous aqueous phase and the oil phase, and the emulsion system is an emulsifier mixture. The adjuvant is characterized in that the emulsion system does not contain an ionic emulsifier and the particle size of the emulsion is between 20 and 200 nanometers. The use of the nanoemulsion adjuvant can prevent toxicity and possible harm of ionic emulsifiers to human cells, and provide a vaccine preparation capable of eliciting a high degree of immune response.
    Type: Application
    Filed: October 26, 2018
    Publication date: May 2, 2019
    Inventors: Ming-Hsi HUANG, Chung-Hsiung HUANG, Chiung-Yi HUANG
  • Publication number: 20190125864
    Abstract: The disclosure relates to a combination of an anti-human VEGFR2 antibody ramucirumab (Ramucirumab or I MC-1121B is a fully human IgG1 specific for the VEGF receptor 2), and abemaciclib (a selective CDK4/6 inhibitor LY2835219), or a pharmaceutically acceptable salt thereof, and to methods of using the combination to treat mantle cell lymphoma (Mantle cell lymphoma -MCL- is an uncommon subtype of non-Hodgkin lymphoma).
    Type: Application
    Filed: April 7, 2017
    Publication date: May 2, 2019
    Inventor: Andrew Edward SCHADE
  • Publication number: 20190125865
    Abstract: The invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods featured in the invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.
    Type: Application
    Filed: October 11, 2018
    Publication date: May 2, 2019
    Inventors: Gianluca Pirozzi, Franck Skobieranda, Yongtao Li, Neil Graham, Steven P. Weinstein
  • Publication number: 20190125866
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: December 21, 2018
    Publication date: May 2, 2019
    Inventors: Piotr BOBROWICZ, Paul WIDBOOM, Michael March SCHMIDT, Jason M. LAJOIE, Robert V. TIGHE, III, Cheuk Lun LEUNG, Ugur ESKIOCAK
  • Publication number: 20190125867
    Abstract: Disclosed is a novel means effective for treatment, metastasis-inhibition, and recurrence-inhibition of human solid cancer. A therapeutic agent for solid cancer according to the present invention comprises as an effective ingredient an anti-CD4 antibody having a high cytotoxic activity, or an anti-CD4 antibody or antigen-binding fragment thereof which antibody or fragment comprises a cytotoxic component bound thereto. Said anti-CD4 antibody is a human-type chimeric antibody, humanized antibody or human antibody against human CD4. The therapeutic agent of the present invention produces still higher effects by combined use with antagonist or agonist against immune checkpoint molecule, small molecule anticancer agents, or the like. The therapeutic agent is also effective in suppressing recurrence and metastasis of solid cancer.
    Type: Application
    Filed: December 27, 2018
    Publication date: May 2, 2019
    Applicants: IDAC THERANOSTICS, INC., THE UNIVERSITY OF TOKYO
    Inventors: Satoru ITO, Shoji YOKOCHI, Kouji MATSUSHIMA, Satoshi UEHA, Yoshiro ISHIWATA